Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 4:16 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,571 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: T cells Clear all

Conditions: Prostatic Neoplasms
Interventions: JNJ-75229414, Bridging Therapy; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 8
States / cities: Duarte, California • Louisville, Kentucky • Minneapolis, Minnesota + 4 more

Conditions: Influenza
Interventions: Fluzone® (intramuscular), FluMist® (intranasal); Biological
Lead sponsor: Stanford University; Other
Eligibility: 8 Years to 100 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Crohn Disease
Interventions: Allogeneic Bone Marrow Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Mycophenolic Acid, Quality-of-Life Assessment, Tacrolimus, Total-Body Irradiation; Procedure · Drug · Other + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: LAVA-1207, LAVA-1207 plus Pembrolizumab; Biological
Lead sponsor: Lava Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: San Francisco, California • Minneapolis, Minnesota • St Louis, Missouri + 3 more

Conditions: Relapsed/Refractory Diffuse Large B-cell Lymphoma, Relapsed/Refractory Mantle Cell Lymphoma
Interventions: Glofitamab; Biological
Lead sponsor: Joshua Brody; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
Interventions: Donor CD34+, CD3+. and belumosudil; Combination Product
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Advanced Hepatocellular Carcinoma
Interventions: Pembrolizumab/Quavonlimab, Lenvatinib, Pembrolizumab; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 7
States / cities: Duarte, California • Baltimore, Maryland • New York, New York + 4 more

Conditions: HIV Infections
Interventions: CD4 Antigens; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1991
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: HIV Infections
Interventions: HST-NEETs; Biological
Lead sponsor: Catherine Bollard; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 3
States / cities: Washington D.C., District of Columbia

Conditions: B Cell Lymphoma, Acute Lymphoblastic Leukemia, Pediatric, Lymphoma
Interventions: Fludarabine, Cyclophosphamide, Autologous CD22 CAR T; Drug
Lead sponsor: Kara Lynn Davis; Other
Eligibility: 1 Year to 30 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Myeloma
Interventions: Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine); Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 18
States / cities: Duarte, California • San Francisco, California • Stanford, California + 13 more

Conditions: Lymphoma, Hodgkin's Disease, Relapse, Lymphoma, Non-Hodgkin
Interventions: TGFbeta resistant LMP-specific CTLs; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2031
U.S. locations: 2
States / cities: Houston, Texas

Conditions: HLA-A*0201 Positive Cells Present, Locally Advanced Malignant Neoplasm, NY-ESO-1 Positive, Unresectable Malignant Neoplasm, Sarcoma
Interventions: 18F-FHBG, Aldesleukin, Busulfan, Cellular Therapy, Computed Tomography, Filgrastim, Fludarabine, Leukapheresis, Plerixafor, Positron Emission Tomography; Other · Biological · Drug + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 16 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Idiopathic CD4-Positive, T-Lymphocytopenia
Interventions: Filgrastim, Plerixafor; Biological · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Transplant-Related Disorder, GVH - Graft Versus Host Reaction
Interventions: CliniMACS® CD34 TCR Alpha/Beta; Device
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: Up to 21 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Cutaneous T-Cell Lymphoma
Interventions: KW-0761, Vorinostat; Biological · Drug
Lead sponsor: Kyowa Kirin, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 34
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 27 more

Conditions: Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions: Vorinostat, Niacinamide, Etoposide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer, Hepatocellular Carcinoma, Urothelial Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Nasopharyngeal Carcinoma, Renal Cell Carcinoma, Non-small Cell Lung Carcinoma, Small Cell Lung Carcinoma, Gastric or Gastroesophageal Junction Adenocarcinoma, Advanced or Metastatic Solid Tumors, Prostate Carcinoma, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Intrahepatic Cholangiocarcinoma, Squamous Cell Anal Cancer, Squamous Cell Penile Carcinoma, Squamous Cell Vulvar Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma
Interventions: XmAb®22841, Pembrolizumab (Keytruda®); Biological
Lead sponsor: Xencor, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 28
States / cities: Encinitas, California • La Jolla, California • Los Angeles, California + 15 more

Conditions: Leukemia, B-cell, Lymphoma, Hodgkins, Lymphoma, Non-hodgkins, Lymphoma, B-Cell
Interventions: Allogeneic stem cell transplant, Anti-CD19-chimeric-antigen-receptor-transduced T cells, Leukapheresis; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 2
States / cities: Bethesda, Maryland • Minneapolis, Minnesota

Conditions: Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus, BK Virus Infection, Immune Deficiency
Interventions: Rapidly generated virus specific T (R-MVST) cells; Drug
Lead sponsor: Monica Bhatia; Other
Eligibility: 3 Months to 26 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma, Newly Diagnosed, Multiple Myeloma (MM)
Interventions: Elranatamab, Daratumumab, Lenalidomide, autologous stem cell transplantation; Drug · Procedure
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 11
States / cities: Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 8 more

Conditions: HIV Infections
Interventions: Lymphocytes, Activated; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lung Adenocarcinoma, Lung Adenosquamous Carcinoma, Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Quality-of-Life Assessment, Radiation Therapy; Procedure · Biological · Other + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 427 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2030
U.S. locations: 169
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Berkeley, California + 129 more

Conditions: Advanced Malignant Solid Tumor
Interventions: RPTR-1-201, PD-1 / PD-L1 monoclonal antibody; Drug
Lead sponsor: Repertoire Immune Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Lake Success, New York • San Antonio, Texas

Search by objective public record fields.

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

Crohn's Allogeneic Transplant Study

Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer

Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

Immunological Tolerance in Patients With Mismatched Kidney Transplants

Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)

An Escalating Dose Tolerance Trial of BG8962 (rCD4) in Patients Who Are HIV Antibody Positive

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies

A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma

Autologous/Allogeneic TGFbeta-resistant LMP-specific CTL, Lymphoma (TGF-beta)

Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL

Phase I Vorinostat in Combination With Niacinamide and Etoposide for Lymphoid Malignancies

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

R-MVST Cells for Treatment of Viral Infections in Children and Young Adults

Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

Evaluation of the Safety and Tolerance of Immunotherapy With Autologous, Ex-Vivo Expanded, HIV-Specific Cytotoxic T-Cells in HIV-Infected Patients With CD4+ Counts Between 100-400/mm3

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors